<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Immunology Infection and Inflam Diseases</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/34B4D5BA-C0A8-41C8-9A93-BFCAF94C3F7A"><gtr:id>34B4D5BA-C0A8-41C8-9A93-BFCAF94C3F7A</gtr:id><gtr:firstName>Kerem</gtr:firstName><gtr:otherNames>Benjamin</gtr:otherNames><gtr:surname>Atalar</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800413"><gtr:id>60E02828-9733-4E09-8950-9AF9E6CC133F</gtr:id><gtr:title>Defining the effects of microRNAs in the activation and lineage commitment of T-cells, and their use as biomarkers of</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0800413</gtr:grantReference><gtr:abstractText>Kidney failure is a serious condition which has an enormous effect on patients? lives. Currently, treatment comes in the form of either a kidney transplant or long-term dialysis. Dialysis is a complicated and time-consuming procedure that requires major changes in a patient?s day-to-day life. By contrast, kidney transplantation offers a much greater degree of freedom for patients and a more normal lifestyle. However, patients with transplants must take lifelong medication to try to keep the transplant healthy. Without this, their body tries to destroy the transplant. A major challenge for kidney doctors is to recognise when the body is beginning to overcome these medications. If doctors can measure this then they may be able to adjust the treatment and save the transplant from damage.

This project aims to find new ways of testing the body?s response to the transplant by studying samples from patients, healthy volunteers and laboratory mice. Results from this study may help to develop a blood test that can help doctors make difficult treatment decisions without taking a kidney transplant sample (biopsy), which is a potentially risky procedure. Additionally, information gained from carrying out this research may help to develop new treatments to keep transplants healthy.</gtr:abstractText><gtr:technicalSummary>Background: The success of renal transplantation in the treatment of end-stage renal failure is limited by the effects of allograft rejection. This is primarily mediated by activated effector CD4+ T-cells which orchestrate the host immune response to the graft. Effector CD4+ T-cell subsets include Th1, Th2 and Th17, each of which has been directly implicated in the pathogenesis of rejection. The process of T-cell differentiation is controlled by the transcription factors T-bet (Th1), GATA3 (Th2) and ROR T (Th17). MicroRNAs are highly conserved short RNA segments which are capable of post-transcriptional gene silencing. Deletion of the enzyme responsible for generating mature microRNAs leads to aberrant T-cell lineage commitment and default to Th1, showing the critical role of microRNAs in T-cell effector function. We have generated data which demonstrates differential expression of microRNAs in T-cell subsets and binding of T-bet and GATA3 to subset-specific microRNA promoter regions.

Hypothesis: T-bet, GATA-3 and ROR T control CD4+ effector T-cell lineage commitment by binding to the promoters of specific microRNAs and controlling their expression.

Aims and Objectives: Identifying these microRNAs and their downstream targets will give insight into fundamental T-cell biology and provide potential biomarkers of renal allograft rejection.

Design and Methodology: Initially I aim to categorise a range of microRNAs defined by their upstream transcriptional control and T-cell subset specific expression. This will be achieved by a focussed methodology which takes results from microRNA expression micro-arrays, highlights candidate microRNAs and then examines their function in vitro. This structured approach will aid discovery of the most important microRNAs in T-cell biology.

Additionally, the T-cell microRNA expression profile of transplant recipients will be examined. Initial experiments will use an in-vivo animal model of transplantation to determine the microRNA profile of acute rejection. A parallel study involving human transplant recipients will prospectively catalogue the microRNA signature of the immune response to transplantation. Results from this can then be correlated with data from both the in-vivo animal model and functional assays to provide insight into the pathological processes that are occurring.

Outcome: This study provides an opportunity to gain further scientific understanding of T-cell lineage commitment and function in the context of renal transplantation. Specific medical opportunities include biomarker discovery and the development of an early, non-invasive diagnostic test for graft rejection. Additionally, new insight into potential therapeutic targets might be gained from understanding the immune mechanisms of graft rejection in greater detail.</gtr:technicalSummary><gtr:fund><gtr:end>2011-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>209841</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Kidney Research UK Fellows Day 2009</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>AC1B8737-89BB-4DD5-AC73-5A821DB12238</gtr:id><gtr:impact>Lay Summary of research produced and presented as part of poster at Kidney Research UK's Annual Fellow's Day

No subsequent impact</gtr:impact><gtr:outcomeId>0673EC7D053</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ASN 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9F09E846-2C02-4538-A706-1E2F56CF23C2</gtr:id><gtr:impact>Presentation of some of my data at an international kidney conference

.</gtr:impact><gtr:outcomeId>AZJCQKBt54N</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>AC63EBF4-4A8E-4299-A4FA-243A9D5574AF</gtr:id><gtr:title>T-cell alloimmunity and chronic allograft dysfunction.</gtr:title><gtr:parentPublicationTitle>Kidney international. Supplement</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8f79b3b082d0af0f2cd8470d59b7efb"><gtr:id>f8f79b3b082d0af0f2cd8470d59b7efb</gtr:id><gtr:otherNames>Safinia N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0098-6577</gtr:issn><gtr:outcomeId>XptykUpDEgM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E17A328-90DB-44FA-81B8-83D56F5FE5BB</gtr:id><gtr:title>Relative roles of Th1 and Th17 effector cells in allograft rejection.</gtr:title><gtr:parentPublicationTitle>Current opinion in organ transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5612980a3fff3de4ff661b27748cd3f5"><gtr:id>5612980a3fff3de4ff661b27748cd3f5</gtr:id><gtr:otherNames>Atalar K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1087-2418</gtr:issn><gtr:outcomeId>9F32F35110A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C6AADB4-6D80-4C39-9B75-7612EA2B559E</gtr:id><gtr:title>Genome-wide sequencing of cellular microRNAs identifies a combinatorial expression signature diagnostic of sepsis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/417d43a7089aa342f399b24e0f14fc1c"><gtr:id>417d43a7089aa342f399b24e0f14fc1c</gtr:id><gtr:otherNames>Ma Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_540e15de15d04d99f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E06F6024-DFB4-4AA0-AD57-AFD70B1DC0F8</gtr:id><gtr:title>Falls, hypokalaemia, and a dry mouth.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5612980a3fff3de4ff661b27748cd3f5"><gtr:id>5612980a3fff3de4ff661b27748cd3f5</gtr:id><gtr:otherNames>Atalar K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>9DD665863FD</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800413</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>2EEE0958-6BE1-4D16-B86B-5D954CD37219</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Renal and Urogenital</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>78E3B265-B307-4D06-9AB7-1F69471E721F</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.4  Surgery</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>